GlassScriptPhysician profile
David Edward Bachofer
NPI 1316058100
$8,776.90
in general payments reported to CMS, 2019-2025
34 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $1,797 · 2021: $1,423 · 2022: $1,197 · 2023: $1,096 · 2024: $975 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,558.74 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $972.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $931.48 | 2019-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $810.35 | 2019-2024 | |
| Glaxosmithkline, LLC. | $780.03 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $481.49 | 2021-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.26 | 2019-2023 | Jardiance |
| Amgen INC. | $400.88 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $370.61 | 2021-2025 | |
| Amarin Pharma, INC. | $345.50 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $251.48 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $218.06 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $168.12 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $147.70 | 2019-2025 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $144.67 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $98.37 | 2022 | |
| Supernus Pharmaceuticals, INC. | $83.64 | 2019-2021 | |
| Esperion Therapeutics, INC. | $68.67 | 2020-2021 | |
| Bausch Health US, LLC | $64.11 | 2023-2024 | Wellbutrin, Aplenzin |
| Kowa Pharmaceuticals America, INC. | $54.85 | 2019-2021 | |
| Allergan, INC. | $51.84 | 2020 | |
| Corcept Therapeutics | $49.09 | 2025 | Korlym |
| Mylan Specialty L.P. | $36.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.39 | 2020-2021 | |
| Genentech USA, INC. | $22.11 | 2021 | |
| Biogen, INC. | $21.74 | 2024 | Skyclarys |
| Axsome Therapeutics, INC. | $20.24 | 2025 | Auvelity |
| Kyowa Kirin, INC. | $20.09 | 2024 | Crysvita |
| Inspire Medical Systems, INC. | $18.09 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $17.78 | 2019 | |
| Horizon Therapeutics Plc | $16.22 | 2022 | |
| Sumitomo Pharma America, INC. | $16.17 | 2024 | Gemtesa |
| Currax Pharmaceuticals LLC | $15.95 | 2023 | Contrave |
| Vivus LLC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bachofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.